Meropenem Atb (Meropenem Trihydrate)

Meropenem, the active ingredient in Meropenem Atb, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It is employed in the treatment of severe bacterial infections, including complicated intra‑abdominal infections, urinary tract infections, bacterial meningitis, and cases of severe sepsis or septic shock in hospitalized patients.

GNH USA supplies Meropenem Atb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global healthcare providers.

Meropenem is a carbapenem antibiotic used to treat serious bacterial infections across several organ systems.

- Complicated intra‑abdominal infections: Provides broad‑spectrum coverage to eradicate Gram‑negative, Gram‑positive and anaerobic pathogens, facilitating clinical resolution. - Complicated urinary tract infections: Achieves rapid bacterial clearance in resistant uropathogens, improving cure rates. - Bacterial meningitis: Penetrates the cerebrospinal fluid to eradicate causative organisms, reducing mortality. - Severe sepsis and septic shock: Delivers bactericidal activity against multidrug‑resistant organisms, supporting hemodynamic stabilization.

Meropenem may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea: mild to moderate loose stools. - Nausea: occasional feeling of queasiness. - Vomiting: intermittent episodes. - Headache: transient cranial discomfort. - Rash: mild skin erythema or pruritus. - Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Severe allergic reactions: anaphylaxis or Stevens‑Johnson syndrome. - Clostridioides difficile colitis: antibiotic‑associated severe diarrhea. - Hemolytic anemia: rare immune‑mediated red cell destruction. - Nephrotoxicity: acute kidney injury in susceptible individuals.

When prescribing Meropenem, clinicians should consider several safety and handling precautions. - Renal function: adjust dose in patients with impaired kidney function. - Hypersensitivity: avoid in individuals with known carbapenem or β‑lactam allergy. - CNS disorders: monitor for seizures in patients with a history of epilepsy or CNS disease. - Pregnancy and lactation: use only if potential benefit outweighs risk, as safety data are limited. - Concomitant antibiotics: assess for additive toxicity when combined with other nephrotoxic or neurotoxic agents. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Valproic acid: may reduce serum valproate levels, risking loss of seizure control. - Probenecid: can increase meropenem plasma concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Aminoglycosides: additive nephrotoxicity; monitor renal function. - Loop diuretics: may enhance ototoxic potential when combined with other ototoxic agents. - Anticoagulants (warfarin): possible alteration of INR; check coagulation parameters. - Other β‑lactam antibiotics: potential for competitive inhibition; assess need for combination therapy.